Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
Mersana Therapeutics, Inc. will provide business updates and report its financial results for Q3 2023 on November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast will be available on the Mersana website.
10/31/2023 - 04:30 PM
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com , and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact: Jason Fredette 617-498-0020jason.fredette@mersana.com
When will Mersana Therapeutics report its financial results for Q3 2023?
Mersana Therapeutics will report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023.
What time will the conference call and webcast start?
The conference call and webcast will start at 8:00 a.m. Eastern Time.
How can I access the conference call?
To access the conference call, please dial 877-270-2148 (domestic) or 412-902-6510 (international).
Where can I watch the live webcast of the presentation?
The live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
Will there be a replay of the webcast?
Yes, a replay of the webcast will be available in the Investors & Media section of the Mersana website for approximately 90 days following the conference call.
MRSN Rankings
#5398 Ranked by Stock Gains
MRSN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About MRSN
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.